Wed, Apr 16, 2014, 6:18 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Athersys, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • machtabow machtabow Aug 25, 2010 1:24 PM Flag

    Why the sell-off??

    They dont have to worry about money. They got the Big Cheese :)

    Pfizer(PFE) has licensed a stem cell therapy for inflammatory bowel disease from Athersys(ATHX).

    ATHX Athersys will received $6 million upfront from Pfizer and is eligible for another $105 million in future milestone payments. Pfizer is paying the costs to develop the stem cell therapy, known as MultiStem, for inflammatory bowel disease.

    MultiStem is made from stem cells obtained from the bone marrow of healthy, adult donors.

    Pfizer will pay royalties to Athersys if MultiStem is approved for sale. Athersys retains the rights to develop MultiStem in various other indications

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ATHX
2.63-0.01(-0.38%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.